VBI Vaccines to Present at the 20th Annual Rodman & Renshaw Global Investment Conference
August 28, 2018 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ:VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Appoints Christopher McNulty as Chief Financial Officer and Head of Business Development
August 15, 2018 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Aug. 15, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company, today announced the appointment of Christopher McNulty as...
VBI Vaccines to Present at the Canaccord Genuity 38th Annual Growth Conference
August 06, 2018 16:15 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ: VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Second Quarter 2018 Financial Results and Provides Corporate Update
July 26, 2018 07:00 ET
|
VBI Vaccines, Inc.
-- Pivotal Phase 3 program for Sci-B-Vac® Hepatitis B vaccine continues to advance towards topline data expected mid-year 2019 -- -- Positive safety and immunogenicity data from Phase 1 study of...
VBI Vaccines to Participate in the 2018 Oppenheimer Boston Oncology Insight Summit
July 09, 2018 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines to Present at 2018 JMP Securities Life Sciences Conference
June 19, 2018 08:00 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., June 19, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) (“VBI”), a commercial-stage biopharmaceutical company developing next-generation infectious disease and...
VBI Vaccines Announces Results of Annual General Meeting
May 25, 2018 16:15 ET
|
VBI Vaccines, Inc.
CAMBRIDGE, Mass., May 25, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (Nasdaq:VBIV) ("VBI" or the "Company"), a commercial-stage biopharmaceutical company developing next-generation infectious...
VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine
May 10, 2018 07:30 ET
|
VBI Vaccines, Inc.
CMV neutralizing antibodies against fibroblast cell infection induced in 100% of subjects who received the highest doseSafe and well-tolerated at all doses with no safety signals observedConference...
VBI Vaccines Announces First Quarter 2018 Financial Results and Provides Corporate Update
May 01, 2018 08:00 ET
|
VBI Vaccines, Inc.
-- Enrollment completed in PROTECT Phase 3 clinical study of Sci-B-Vac® Hepatitis B Vaccine -- -- Key upcoming milestones in 2018 for lead eVLP vaccine candidates, VBI-1501 for prevention of...
VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine
April 19, 2018 08:00 ET
|
VBI Vaccines, Inc.
More than 1,600 subjects enrolled in PROTECT studyTopline data expected mid-2019 CAMBRIDGE, Mass., April 19, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. (NASDAQ:VBIV) (“VBI”) today announced...